Catalyst Pharmaceuticals, Inc. (CPRX) 

Catalyst Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients. The company also develops Firdapse for the treatment of MuSK antibody positive myasthenia gravis, and spinal muscular atrophy type 3, as well as to treat hereditary neuropathy with liability to pressure palsies. It has license agreements with BioMarin Pharmaceutical Inc.; and collaboration and license agreement with Endo Ventures Limited for the development and commercialization of generic Sabril tablets. The company was formerly known as Catalyst Pharmaceutical Partners, Inc. and changed its name to Catalyst Pharmaceuticals, Inc. in May 2015. Catalyst Pharmaceuticals, Inc. was founded in 2002 and is based in Coral Gables, Florida.

Show less

Over the last 12 months, insiders at Catalyst Pharmaceuticals, Inc. have bought $0 and sold $6.12M worth of Catalyst Pharmaceuticals, Inc. stock.

On average, over the past 5 years, insiders at Catalyst Pharmaceuticals, Inc. have bought $113,405 and sold $11.09M worth of stock each year.

There was no buying activity among insiders over the last 12 months.

The last purchase of 30,000 shares for transaction amount of $89,100 was made by MCENANY PATRICK J (President and CEO) on 2020‑09‑30.